Skip to main content

Clinical Trials Using CD19-targeting Agent

Review the clinical trials studying cd19-targeting agent on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 59

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 199 locations
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 199 locations
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Active
Location: 429 locations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment with Blinatumomab for Children, Adolescents, and Young Adults with Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 125 locations
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Status: Active
Location: 199 locations
A Phase 2 Study Adding the Drugs Tazemetostat or Zanubrutinib to Usual Treatment for People with Large B-Cell Lymphoma that Returned or Did Not Respond to Earlier Treatment
Status: Active
Location: 122 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 101 locations
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Status: Active
Location: 253 locations
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Status: Active
Location: 12 locations
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Status: Active
Location: 10 locations
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Status: Active
Location: 10 locations
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Status: Active
Location: 8 locations
Zanubrutinib and Tafasitamab for the Treatment of Relapsed or Untreated Mantle Cell Lymphoma
Status: Active
Location: 8 locations
Epcoritamab with Lenalidomide and Tafasitamab for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, ECLAT Trial
Status: Active
Location: 7 locations
Total Therapy for Infants with Acute Lymphoblastic Leukemia, The TINI 2 Study
Status: Active
Location: 7 locations
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Status: Active
Location: 7 locations
Loncastuximab Tesirine in Combination with Rituximab for the Treatment of Relapsed/Refractory Follicular Lymphoma
Status: Active
Location: 7 locations
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 6 locations
Loncastuximab Tesirine for the Treatment of Previously Treated Waldenstrom Macroglobulinemia
Status: Active
Location: 5 locations
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Status: Active
Location: 7 locations
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: 4 locations
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: 4 locations
ASCIMINIB, Dasatinib, Prednisone, and Blinatumomab in Treating Patients with BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, or Chronic Myeloid Leukemia
Status: Active
Location: 4 locations
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Status: Active
Location: 4 locations
Loncastuximab Tesirine and Rituximab followed by DA-EPOCH-R for Treating Patients with High-Risk Diffuse Large B-cell Lymphoma
Status: Active
Location: 3 locations